Those assigned to write about traumatic experiences mounted
a greater vaccine response by producing more antibodies.
Not exact matches
The problem with traditional methods of
vaccine development is that they depend on a
great deal of trial and error: researchers develop a compound they think should cause an immune
response in the body and then test it on thousands of people, hoping to see a positive change.
Beyond the issue of alleviating real and potential shortages of influenza -
vaccine supplies is the possibility of pursuing vaccination strategies that would induce optimal immunity among populations of persons who not only are at
greatest risk for complications but who also generally do not mount an optimal immune
response.
To be certain the Th2 type immunopathology was elicited by the S protein
vaccine in our studies and in hopes a
greater immune
response would result from higher dosages of the
vaccine and induce
greater protection against infection as well as reduce or prevent the immunopathology, our experiment 2 used up to 9 µg of the S protein for immunization.
Vaccines are used to offer protection against a number of diseases and so ensuring their effectiveness is important, and a study published in the journal Vaccine has reported that flu vaccines given in the morning brought about a greater immune (measured by antibody levels) response than those given in the af
Vaccines are used to offer protection against a number of diseases and so ensuring their effectiveness is important, and a study published in the journal
Vaccine has reported that flu
vaccines given in the morning brought about a greater immune (measured by antibody levels) response than those given in the af
vaccines given in the morning brought about a
greater immune (measured by antibody levels)
response than those given in the afternoon.
Glenda Gray, executive director of the Wits Health Consortium's perinatal HIV research unit in South Africa, presented data today at the HIV R4P conference in Cape Town indicating that the prime - boost
vaccine candidates initially tested in the RV144 trial in Thailand — the only HIV
vaccine trial to date to show any efficacy — induced cross-clade immune
responses in a Phase I safety trial conducted in South Africa, with immunogenicity similar to or
greater than that of the
responses induced in Thai volunteers.
As livestock production and the rate of pet ownership both continue to increase in
response to rising demand and increased standard of living, animal health medicines and
vaccines will also be needed in
greater volumes.
It turns out the
response to the
vaccine has been variable between different Clades and there is a
great deal (up to 15 %) of genetic variability even within the same Clade.
This is because the second vaccination will produce a much
greater (logarithmically
greater)
response if it is following a
vaccine given 2 - 4 weeks prior.